# Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che

Source: https://onco.cc/trials/nct06841055/  
OnCo record `nct06841055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PM8002, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.

## Summary

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment is a phase 2 interventional study registered as NCT06841055 by BioNTech SE, with 60 participants planned, started 2025-03-03 and due to reach its primary completion in 2028-10. Interventions recorded: Pumitamig, Docetaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06841055
- Phase: 2
- Setting: A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)
- Sponsor: BioNTech SE
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06841055: https://clinicaltrials.gov/study/NCT06841055

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06841055.json